J&J Drug Combo Shows Promise in Treating Lung Cancer
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
Source: hngn.com
Page 6 - J Amp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from J Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In J Amp Today - Breaking & Trending Today
/cloudfront-us-east-1.images.arcpublishing.com/tgam/OWX3SYK5QFKBZEXWU6FTIBVMJU.jpg)
Short sellers return to profit in August as U.S. stocks rally pauses
The bearish investors made $14.8 billion on aggregate last month after shedding $16.5 billion in July
Source: theglobeandmail.com
Pharmaceutical giants 'bullied' SA into signing 'one-sided' Covid-19 contracts, says NPO
The Health Justice Initiative on Tuesday labelled the contracts the government signed with pharmaceutical manufacturers and suppliers during the height of the Covid-19 pandemic as one-sided and unethical.
Source: jacarandafm.com
South Africa overpaid for Covid-19 vaccines: Health Justice Initiative
The contracts that South Africa signed to procure Covid-19 vaccines showed the country was forced to overpay for vaccines and the terms and conditions were overwhelmingly one-sided and favoured multinational corporations.
Source: timeslive.co.za
J&J, Lupin cut prices for tuberculosis drug in lower-income countries
Johnson & Johnson and Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, according to the Stop TB Partnership. The new prices, $130 for J&J and $194 for Lupin for a six-month course of treatment, represent a 55% and 33% reduction, respectively. Bedaquiline is a key part of recommended treatment regimens for drug-resistant TB infections, and this price reduction will help broaden access to the life-saving drug.
Source: indiatimes.com